Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 78 of 95, showing 5 Applications out of 474 total, starting on record 386, ending on 390

# Protocol No Study Title Investigator(s) & Site(s)

386.

ECCT/15/01/05   In vivo efficacies of AL and DP
    Open label randomized study evaluating the in vivo efficacies of Artemether-lumefantrine and Dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in children under five years of age in western Kenya.   
Principal Investigator(s)
1. AAron Samuels
2. Simon Kariuki
Site(s) in Kenya
Siaya District Hospital
 
View

387.

ECCT/15/01/03   Simplifying ShangRing Circumcision for Men and Boys
    Simplifying the Shang Ring Technique for Circumcision of Men and Boys   
Principal Investigator(s)
1. Mark Barone
Site(s) in Kenya
1. Homa Bay Level IV hospital (Homa Bay county)
2. Vipingo Health Centre (Kilifi county)
 
View

388.

ECCT/15/01/02  
      Study title  An observational pilot study to characterize the immune response  induced by the commercial Varicella Zoster Virus vaccine  Zostavax® (Merck) in healthy adult females in Nairobi, Kenya.  Clinical Phase IV      
Principal Investigator(s)
1. Prof Walter Jaoko Jaoko
Site(s) in Kenya
KAVI-INSTITUTE OF CLINICAL RESEARCH (KAVI-ICR)
 
View

389.

ECCT/14/12/01   Rivaroxaban for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE)
    XALIA LEA- Xarelto® for Long-term and  Initial Anticoagulation in Venous  Thromboembolism (VTE) in Latin America,  EMEA and Asia   
Principal Investigator(s)
1. Anne Njeri Mugera Njambi Mugera
2. Dr. Martin N Wanyoike Njoroge Wanyoike
3. Charles Muthui Kariuki Muthui Kariuki
4. FEROZ ALI Allibhoy
Site(s) in Kenya
1. Primecare Heart Clinic (Nairobi City county)
2. Dr. Silversteins Clinic (Nairobi City county)
3. Nairobi Cardiovascular Clinic (Nairobi City county)
4. Agah Khan Kisumu (Kisumu county)
 
View

390.

ECCT/14/11/02   A5297
    An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and < 500 cells/mm3   
Principal Investigator(s)
1. VICTOR AKELO
Site(s) in Kenya
KEMRI/CDC CLINICAL RESEARCH CENTRE
 
View